{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The study will measure patient survival at 6 months but will continue to monitor overall survival as a secondary objective. The Kaplan-Meier method will be used.","groups":[{"description":"Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.\n\nCarfilzomib: Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.\n\nDexamethasone: Administered prior to administration of Study drug\n\nAcyclovir: Administered orally twice daily","id":"OG000","title":"Carfilzomib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"8 patients did not complete treatment and were not included in the analysis.","reportingStatus":"POSTED","timeFrame":"Baseline through 6 months for evaluating all patients","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Participants"}